NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
During ESMO ’24 in Barcelona, I had the pleasure to show first data from a new HIF-2 inhibitor by the name NKT2152. Dr. Eric Jonasch presented the data and I was the senior author. It’s a group effort. The HIF-2 inhibitors are coming in renal cell cancer. We have a drug by the name belzutifan approved in the refractory setting in VHL syndrome and it’s been integrated in many trials in the front line, in the adjuvant setting, etc. This second, I would say this other HIF-2 inhibitor, showed a response rate of 20%. The interesting thing about it is that the toxicity in terms of on-target toxicity targeting HIF-2 were similar to belzutifan, mostly anaemia and hypoxia. Erythropoietin also went down, this is similar to what we saw with belzutifan.
One of the major differences is the long half-life. This is why, after exploring multiple cohorts and multiple doses, we are going now into two different doses that include a loading dose as well as a weekly or daily dose that we are exploring. But it’s refreshing to see another HIF-2 inhibitor response rate, active drug, and hopefully this will benefit patients one day and will lead to a pivotal phase III trial.
